Pacira BioSciences Reports Director/Officer Changes

TL;DR

Pacira BioSciences (PCRX) filed an 8-K for director/officer changes effective 9/26.

AI Summary

Pacira BioSciences, Inc. filed an 8-K on September 27, 2024, reporting changes effective September 26, 2024. The filing pertains to the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements for certain officers. Specific details regarding the individuals involved and the nature of these changes were not provided in the excerpt.

Why It Matters

Changes in a company's board of directors or executive officers can signal shifts in strategy, governance, or operational focus.

Risk Assessment

Risk Level: medium — Changes in key leadership roles can indicate underlying issues or strategic shifts that may impact the company's future performance.

Key Players & Entities

• Pacira BioSciences, Inc. (company) — Registrant
• September 26, 2024 (date) — Effective date of reported changes
• September 27, 2024 (date) — Filing date of the 8-K

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share PCRX Nasdaq Global Select Mar
• $374,700 — . Riker's current annual base salary is $374,700 per year, which is not being adjusted i
• $75,000 b — ncial Officer, Ms. Riker will receive a $75,000 bonus which is repayable to the Company i

Filing Documents

• pcrx-20240926.htm (8-K) — 27KB
• 0001396814-24-000124.txt ( ) — 149KB
• pcrx-20240926.xsd (EX-101.SCH) — 2KB
• pcrx-20240926_lab.xml (EX-101.LAB) — 21KB
• pcrx-20240926_pre.xml (EX-101.PRE) — 12KB
• pcrx-20240926_htm.xml (XML) — 3KB

From the Filing

pcrx-20240926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 26, 2024 PACIRA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-35060 51-0619477 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 5401 West Kennedy Boulevard, Suite 890 Tampa , Florida 33609 (Address and Zip Code of Principal Executive Offices) ( 813 ) 553-6680 (Registrant's Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol Name of each exchange on which registered Common Stock, par value $0.001 per share PCRX Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on February 26, 2024, Pacira BioSciences, Inc. (the "Company") and Charles A. Reinhart, III, the Company's Chief Financial Officer, agreed that he would depart the Company effective September 30, 2024, and will continue to serve as consultant to the Company for a period of nine months thereafter. On September 26, 2024, the Board of Directors of the Company (the "Board") appointed Lauren Riker, the Company's current Senior Vice President of Finance and principal accounting officer, to also serve as interim Chief Financial Officer of the Company (including as principal financial officer and continuing as principal accounting officer for Securities and Exchange Commission reporting purposes), effective October 1, 2024. Ms. Riker is expected to remain in this interim role until a permanent successor to Mr. Reinhart is identified. Ms. Riker, age 46, has been with the Company since May 2011 and has most recently served as the Company's Senior Vice President of Finance since December 2021. There are no arrangements or understandings between Ms. Riker and any person pursuant to which Ms. Riker was selected to serve as interim Chief Financial Officer, other than her existing employment relationship. There are no family relationships between Ms. Riker and any director or executive officer of the Company, and Ms. Riker is not a party to any transaction that would require disclosure pursuant to Item 404(a) of Regulation S-K involving the Company or any of its subsidiaries. As an executive officer of the Company, Ms. Riker has an existing executive employment agreement with the Company's operating subsidiary, Pacira Pharmaceuticals, Inc., a California corporation (as amended to date, the "Employment Agreement"), which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024. Ms. Riker's current annual base salary is $374,700 per year, which is not being adjusted in connection with her appointment as interim Chief Financial Officer, and is subject to annual increase by the Board. Ms. Riker also participates in the Company's annual cash incentive bonus program for executive officers, with her current annual incentive target set at 50% of her annual base salary, which is not being adjusted in connection with her appointment as interim Chief Financial Officer. Ms. Riker is also currently a participant in the Company's cash-based long-term incentive plan for executives, and her incentive target for such program is also not being adjusted in connection with her appointment as interim Chief Financial Officer. In connection with her appointment as interim Chief Financial Officer, Ms. Riker will receive a $75,000 bonus which is repayable to the Company in the event that, within one year of payment, Ms. Riker's employment is terminated for

View Full Filing

View this 8-K filing on SEC EDGAR